Obsidian Therapeutics (NASDAQ:OBX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Posted by Casey Walker on Sep 9th, 2026

Shares of Obsidian Therapeutics (NASDAQ:OBX – Get Free Report) have been given an average recommendation of “Moderate Buy” by the six brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $42.50.

A number of research analysts have commented on the company. Weiss Ratings assumed coverage on Obsidian Therapeutics in a report on Wednesday, September 2nd. They set a “sell (d-)” rating on the stock. Lifesci Capital started coverage on Obsidian Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating and a $43.00 price objective on the stock. William Blair started coverage on Obsidian Therapeutics in a research note on Wednesday. They set an “outperform” rating on the stock. Piper Sandler started coverage on shares of Obsidian Therapeutics in a report on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price objective for the company. Finally, Zacks Research upgraded shares of Obsidian Therapeutics to a “hold” rating in a research note on Thursday, August 6th.

Get Our Latest Research Report on OBX

Obsidian Therapeutics Stock Up 11.4%

Shares of OBX opened at $18.73 on Wednesday. Obsidian Therapeutics has a 52-week low of $14.57 and a 52-week high of $49.97.

Obsidian Therapeutics Company Profile

(Get Free Report)

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.